Global KRAS Inhibitors Market Research Report 2023: A $4 Billion Opportunity by 2029, 200% Growth in 2022, 60 Drugs in Clinical Trials, 2 Approved Drugs
June 07, 2023 10:18 ET
|
Research and Markets
Dublin, June 07, 2023 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. ...
Medigene Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs
June 01, 2023 07:00 ET
|
Medigene AG
Medigene is building a broad KRAS library consisting of multiple T cell receptors (TCRs) targeting multiple KRAS mutations and multiple HLAs, covering large patient populations suffering from...
Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
May 24, 2023 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
May 08, 2023 16:02 ET
|
Revolution Medicines, Inc.
First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) – progressing on plan Appointment of chief medical officer and key leaders across...
Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023
May 01, 2023 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference
April 13, 2023 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
April 06, 2023 07:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
March 07, 2023 16:02 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
March 05, 2023 18:30 ET
|
Immuneering Corporation
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid...
Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock
March 02, 2023 21:15 ET
|
Revolution Medicines, Inc.
REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...